<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/247d–10" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/247d–10/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/247d–10/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_247d_10"><akn:num>247d–10</akn:num><akn:heading>Pilot program for public health laboratories to detect fentanyl and other synthetic opioids</akn:heading><akn:content><akn:p>§ 247d–10. Pilot program for public health laboratories to detect fentanyl and other synthetic opioids(a) GrantsThe Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall award grants to, or enter into cooperative agreements with, Federal, State, and local agencies to improve coordination between public health laboratories and laboratories operated by law enforcement agencies, such as Customs and Border Protection and the Drug Enforcement Administration, to improve detection of synthetic opioids, including fentanyl and its analogues, as described in subsection (b).


(b) Detection activitiesThe Secretary, in consultation with the Director of the National Institute of Standards and Technology, the Director of the Centers for Disease Control and Prevention, the Attorney General of the United States, and the Administrator of the Drug Enforcement Administration, shall, for purposes of this section, develop or identify—(1) best practices for safely handling and testing synthetic opioids, including fentanyl and its analogues, including with respect to reference materials, instrument calibration, and quality control protocols;

(2) reference materials and quality control standards related to synthetic opioids, including fentanyl and its analogues, to enhance—(A) clinical diagnostics;

(B) postmortem data collection; and

(C) portable testing equipment utilized by law enforcement and public health officials; and


(3) procedures for the identification of new and emerging synthetic opioid formulations and procedures for reporting those findings to appropriate law enforcement agencies and Federal, State, and local public health laboratories and health departments, as appropriate.


(c) LaboratoriesThe Secretary shall require recipients of grants or cooperative agreements under subsection (a) to—(1) follow the best practices established under subsection (b) and have the appropriate capabilities to provide laboratory testing of controlled </akn:p></akn:content><akn:subsection eId="subsec_247d_10_a"><akn:num>(a)</akn:num><akn:heading>Grants</akn:heading><akn:content><akn:p>(a) Grants The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall award grants to, or enter into cooperative agreements with, Federal, State, and local agencies to improve coordination between public health laboratories and laboratories operated by law enforcement agencies, such as Customs and Border Protection and the Drug Enforcement Administration, to improve detection of synthetic opioids, including fentanyl and its analogues, as described in subsection (b).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_247d_10_b"><akn:num>(b)</akn:num><akn:heading>Detection activities</akn:heading><akn:content><akn:p>(b) Detection activities The Secretary, in consultation with the Director of the National Institute of Standards and Technology, the Director of the Centers for Disease Control and Prevention, the Attorney General of the United States, and the Administrator of the Drug Enforcement Administration, shall, for purposes of this section, develop or identify—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_247d_10_c"><akn:num>(c)</akn:num><akn:heading>Laboratories</akn:heading><akn:content><akn:p>(c) Laboratories The Secretary shall require recipients of grants or cooperative agreements under subsection (a) to—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_247d_10_d"><akn:num>(d)</akn:num><akn:heading>Authorization of appropriations</akn:heading><akn:content><akn:p>(d) Authorization of appropriations To carry out this section, there is authorized to be appropriated $15,000,000 for each of fiscal years 2019 through 2023.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>